Home›Companies›Biotech & Pharma›Tolerance Bio

Tolerance Bio Inc.

Develops thymus-based therapies for people with immune-mediated diseases.

Updated Nov 10, 2026·Latest SEC filing Jun 18, 2026·Suggest an edit

About Tolerance Bio

Tolerance Bio is a private company based in Philadelphia, Pennsylvania, incorporated in 2023 in Delaware. It has reported $15,101,584 raised in one offering on Form D since June 2026. Its chief executive is Francisco Leon.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Jun 3, 2026Jun 18, 2026$15,101,584target not set13$1.1MEquityRule 506(b)Form D ↗

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on Tolerance Bio's Form D filed Jun 18, 2026.

Philip Ball
Philip Ball
SVP, Head of Business Development and Operations, director
DC
Justin Vogel
Justin Vogel
Chief Financial Officer and director
Francisco Leon
Francisco Leon
Founder and CEO, director
Also a director at Lapix Therapeutics and Paulex Bio.

Sources

  1. SECTolerance Bio Inc. filing history
  2. CompanyTolerance Bio team
  3. PressTolerance Bio and ZipCode Bio collaboration